Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service skin substitutes & wound grafts cases in North Carolina: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (246 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 32 | 6,015 | 40% |
| 2020 | 37 | 6,393 | 43% |
| 2021 | 33 | 6,360 | 48% |
| 2022 | 32 | 6,121 | 52% |
| 2023 | 34 | 7,159 | 56% |
| 2024 | 35 | 7,475 | 59% |
| 2025 from claims | – | 8,318 7,634–8,800 | 61% |
| 2026 forecast | – | 8,787 7,731–10,139 | 62% |
| 2027 forecast | – | 9,262 7,918–11,037 | 62% |
| 2028 forecast | – | 9,759 8,143–11,949 | 63% |
| 2029 forecast | – | 10,278 8,395–12,889 | 64% |
| 2030 forecast | – | 10,819 8,668–13,865 | 65% |
Application of cellular and tissue-based products to wounds; the loudest category in Open Payments. Professional codes (what the surgeon bills): CPT 15271, 15273, 15275, 15277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 55% of the cases CMS names in North Carolina; 20 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 3% inpatient hospital, 31% hospital outpatient, 66% office. The share outside the hospital has moved +20 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Office |
|---|---|---|---|
| 2026 · ~8,800 | ~260 | ~2,600 | ~5,900 |
| 2027 · ~9,300 | ~280 | ~2,700 | ~6,200 |
| 2028 · ~9,800 | ~300 | ~2,900 | ~6,600 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 29% (31% in 2025), office about 68% (66% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 307 | 65,607+28%/yr | +28%/yr | 16.8 | 81% | 135,200 in 2030+13%/yr |
| Texas | 193 | 48,756+22%/yr | +22%/yr | 13.2 | 77% | 79,300 in 2030+8.4%/yr |
| Georgia | 65 | 14,399+9.3%/yr | +9.3%/yr | 9.7 | 74% | 20,000 in 2030+5.6%/yr |
| Oklahoma | 48 | 11,719+21%/yr | +21%/yr | 16.6 | 72% | 19,200 in 2030+8.6%/yr |
| Tennessee | 38 | 9,735+16%/yr | +16%/yr | 8.3 | 69% | 15,600 in 2030+8.1%/yr |
| Virginia | 47 | 9,709+14%/yr | +14%/yr | 6.5 | 70% | 21,900 in 2030+14%/yr |
| South Carolina | 44 | 8,777+14%/yr | +14%/yr | 8.4 | 72% | 16,300 in 2030+11%/yr |
| Mississippi | 39 | 8,487+28%/yr | +28%/yr | 15.3 | 68% | 14,900 in 2030+9.8%/yr |
| Alabama | 31 | 7,567+19%/yr | +19%/yr | 9.4 | 82% | 11,800 in 2030+7.7%/yr |
| Kentucky | 24 | 7,085+18%/yr | +18%/yr | 9.2 | 65% | 11,400 in 2030+8.3%/yr |
| Louisiana | 33 | 6,694+10%/yr | +10%/yr | 9.4 | 82% | 12,700 in 2030+11%/yr |
| Maryland | 25 | 5,850+12%/yr | +12%/yr | 5.3 | 70% | 12,200 in 2030+13%/yr |
| Arkansas | 17 | 4,095+20%/yr | +20%/yr | 7.1 | 73% | 6,940 in 2030+9.2%/yr |
| West Virginia | 12 | 3,280+21%/yr | +21%/yr | 9.3 | 82% | 4,240 in 2030+4.4%/yr |
| Delaware | 5 | 1,763+16%/yr | +16%/yr | 7.8 | 92% | 3,650 in 2030+13%/yr |
| District of Columbia | 4 | 1,007+12%/yr | +12%/yr | 11.6 | 83% | 2,200 in 2030+14%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Debridement & negative-pressure wound therapy | 411 | 84,720−6.3%/yr | −6.3%/yr | 81.10.7× | 34% | 87,500 in 2030+0.5%/yr |
| Bone graft & orthobiologics | 14 | 525−14%/yr | −14%/yr | 0.50.7× | 2% | 520 in 2030−0.2%/yr |
Skin substitutes & wound grafts in every state, and its device makers · Every procedure market in North Carolina · Every state · Compare with Florida
Kerecis leads with 30% of company spending on these surgeons in 2025, −9 pts on 2024.
In 2025, 30 companies reported engagement with North Carolina’s surgeons worth $557K in consulting, speaking, meals and travel tied to these products, about $16K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 37 clearances and approvals in the category, 13 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
For CPT 15271 (appl skin sub t/arm/l 1st 25/<), commercial plans pay North Carolina’s hospitals a median of $729, from $578 at the lowest to $3,217 at the highest, across 8 hospitals that publish a price.
Each hospital’s median over its commercial plans, from the machine-readable files hospitals must post; not every hospital is loaded.